Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.

Brosseron F, Traschütz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, Jessen F, Heneka MT.

Alzheimers Res Ther. 2018 Feb 26;10(1):25. doi: 10.1186/s13195-018-0353-3.

2.

Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease.

Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP, Griep A, Gelpi E, Beilharz M, Riedel D, Golenbock DT, Geyer M, Walter J, Latz E, Heneka MT.

Nature. 2017 Dec 20;552(7685):355-361. doi: 10.1038/nature25158.

PMID:
29293211
3.

Variability and temporal dynamics of novel object recognition in aging male C57BL/6 mice.

Traschütz A, Kummer MP, Schwartz S, Heneka MT.

Behav Processes. 2018 Dec;157:711-716. doi: 10.1016/j.beproc.2017.11.009. Epub 2017 Nov 15.

PMID:
29155004
4.

Proteome profiling of s-nitrosylated synaptosomal proteins by isobaric mass tags.

Wijasa TS, Sylvester M, Brocke-Ahmadinejad N, Kummer MP, Brosseron F, Gieselmann V, Heneka MT.

J Neurosci Methods. 2017 Nov 1;291:95-100. doi: 10.1016/j.jneumeth.2017.08.005. Epub 2017 Aug 5. No abstract available.

5.

Effects of macrophage-dependent peroxisome proliferator-activated receptor γ signalling on adhesion formation after abdominal surgery in an experimental model.

Hong GS, Schwandt T, Stein K, Schneiker B, Kummer MP, Heneka MT, Kitamura K, Kalff JC, Wehner S.

Br J Surg. 2015 Nov;102(12):1506-16. doi: 10.1002/bjs.9907. Epub 2015 Aug 27.

PMID:
26313905
6.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

7.

CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model.

Krauthausen M, Kummer MP, Zimmermann J, Reyes-Irisarri E, Terwel D, Bulic B, Heneka MT, Müller M.

J Clin Invest. 2015 Jan;125(1):365-78. doi: 10.1172/JCI66771. Epub 2014 Dec 15.

8.

Truncated and modified amyloid-beta species.

Kummer MP, Heneka MT.

Alzheimers Res Ther. 2014 May 26;6(3):28. doi: 10.1186/alzrt258. eCollection 2014. Review.

9.

SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.

Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E, Kummer MP, Cruchaga C, Hoffmann P, Teunissen C, Holstege H, Kornhuber J, Peters O, Naj AC, Chouraki V, Bellenguez C, Gerrish A; International Genomics of Alzheimer's Project (IGAP); Alzheimer's Disease Neuroimaging Initiative (ADNI), Heun R, Frölich L, Hüll M, Buscemi L, Herms S, Kölsch H, Scheltens P, Breteler MM, Rüther E, Wiltfang J, Goate A, Jessen F, Maier W, Heneka MT, Becker T, Nöthen MM.

Hum Mol Genet. 2014 Dec 15;23(24):6644-58. doi: 10.1093/hmg/ddu372. Epub 2014 Jul 15.

10.

Ear2 deletion causes early memory and learning deficits in APP/PS1 mice.

Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele G, Witten A, Figura S, Stoll M, Schwartz S, Pape HC, Schultze JL, Weinshenker D, Heneka MT, Urban I.

J Neurosci. 2014 Jun 25;34(26):8845-54. doi: 10.1523/JNEUROSCI.4027-13.2014. Erratum in: J Neurosci. 2015 Feb 4;35(5):2321. Urban, Inga [Added].

11.

Innate immune activation in neurodegenerative disease.

Heneka MT, Kummer MP, Latz E.

Nat Rev Immunol. 2014 Jul;14(7):463-77. doi: 10.1038/nri3705. Review.

PMID:
24962261
12.

Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits.

Kummer MP, Schwarzenberger R, Sayah-Jeanne S, Dubernet M, Walczak R, Hum DW, Schwartz S, Axt D, Heneka MT.

Mol Neurobiol. 2015 Apr;51(2):661-71. doi: 10.1007/s12035-014-8743-4. Epub 2014 May 17.

13.

Postoperative ileus involves interleukin-1 receptor signaling in enteric glia.

Stoffels B, Hupa KJ, Snoek SA, van Bree S, Stein K, Schwandt T, Vilz TO, Lysson M, Veer CV, Kummer MP, Hornung V, Kalff JC, de Jonge WJ, Wehner S.

Gastroenterology. 2014 Jan;146(1):176-87.e1. doi: 10.1053/j.gastro.2013.09.030. Epub 2013 Sep 22.

PMID:
24067878
14.

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.

Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI.

Alzheimers Res Ther. 2013 Apr 29;5(2):21. doi: 10.1186/alzrt175. eCollection 2013. Review.

15.

NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.

Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT.

Nature. 2013 Jan 31;493(7434):674-8. doi: 10.1038/nature11729. Epub 2012 Dec 19.

16.

Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing.

Kummer MP, Vogl T, Axt D, Griep A, Vieira-Saecker A, Jessen F, Gelpi E, Roth J, Heneka MT.

J Neurosci. 2012 Dec 5;32(49):17824-9. doi: 10.1523/JNEUROSCI.1504-12.2012.

17.

PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.

Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT.

J Neurosci. 2012 Nov 28;32(48):17321-31. doi: 10.1523/JNEUROSCI.1569-12.2012.

18.

Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice.

Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape HC, Rommelfanger KS, Schroeder JP, Stoll M, Schultze J, Weinshenker D, Heneka MT.

Biol Psychiatry. 2013 Mar 1;73(5):454-63. doi: 10.1016/j.biopsych.2012.06.013. Epub 2012 Aug 9.

19.

Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.

Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP.

Curr Neuropharmacol. 2011 Dec;9(4):643-50. doi: 10.2174/157015911798376325.

20.

Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease.

Rapic S, Backes H, Viel T, Kummer MP, Monfared P, Neumaier B, Vollmar S, Hoehn M, Van der Linden A, Heneka MT, Jacobs AH.

Neurobiol Aging. 2013 Jan;34(1):351-4. doi: 10.1016/j.neurobiolaging.2012.04.016. Epub 2012 May 30.

PMID:
22651996
21.

Nitric oxide decreases the enzymatic activity of insulin degrading enzyme in APP/PS1 mice.

Kummer MP, Hülsmann C, Hermes M, Axt D, Heneka MT.

J Neuroimmune Pharmacol. 2012 Mar;7(1):165-72. doi: 10.1007/s11481-011-9339-7. Epub 2012 Jan 8.

PMID:
22227962
22.

Steerable intravitreal inserts for drug delivery: in vitro and ex vivo mobility experiments.

Bergeles C, Kummer MP, Kratochvil BE, Framme C, Nelson BJ.

Med Image Comput Comput Assist Interv. 2011;14(Pt 1):33-40.

PMID:
22003597
23.

Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation.

Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, Walter J, Pape HC, König S, Roeber S, Jessen F, Klockgether T, Korte M, Heneka MT.

Neuron. 2011 Sep 8;71(5):833-44. doi: 10.1016/j.neuron.2011.07.001.

24.

Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease.

Mildner A, Schlevogt B, Kierdorf K, Böttcher C, Erny D, Kummer MP, Quinn M, Brück W, Bechmann I, Heneka MT, Priller J, Prinz M.

J Neurosci. 2011 Aug 3;31(31):11159-71. doi: 10.1523/JNEUROSCI.6209-10.2011.

25.

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.

Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K.

Alzheimers Dement. 2011 Jul;7(4):386-395.e6. doi: 10.1016/j.jalz.2011.05.2243. Erratum in: Alzheimers Dement. 2011 Sep;7(5):556.

26.

Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis.

Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT.

J Neurosci. 2011 May 11;31(19):7049-59. doi: 10.1523/JNEUROSCI.6546-10.2011.

27.

Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease.

Heneka MT, Kummer MP, Weggen S, Bulic B, Multhaup G, Münter L, Hüll M, Pflanzner T, Pietrzik CU.

Curr Alzheimer Res. 2011 Mar;8(2):115-31. Review.

PMID:
21345168
28.

Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice.

Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Thiele A, Heneka MT.

Neuroscience. 2011 Mar 10;176:396-407. doi: 10.1016/j.neuroscience.2010.11.052. Epub 2010 Dec 1.

PMID:
21129451
29.

Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice.

Rey NL, Jardanhazi-Kurutz D, Terwel D, Kummer MP, Jourdan F, Didier A, Heneka MT.

Neurobiol Aging. 2012 Feb;33(2):426.e1-11. doi: 10.1016/j.neurobiolaging.2010.10.009. Epub 2010 Nov 24.

PMID:
21109328
30.

Restraint stress increases neuroinflammation independently of amyloid β levels in amyloid precursor protein/PS1 transgenic mice.

Perez Nievas BG, Hammerschmidt T, Kummer MP, Terwel D, Leza JC, Heneka MT.

J Neurochem. 2011 Jan;116(1):43-52. doi: 10.1111/j.1471-4159.2010.07083.x. Epub 2010 Dec 2.

31.

Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptides (i).

Fleisher-Berkovich S, Filipovich-Rimon T, Ben-Shmuel S, Hülsmann C, Kummer MP, Heneka MT.

J Neuroinflammation. 2010 Oct 11;7:61. doi: 10.1186/1742-2094-7-61.

32.

Neuroinflammatory processes in Alzheimer's disease.

Heneka MT, O'Banion MK, Terwel D, Kummer MP.

J Neural Transm (Vienna). 2010 Aug;117(8):919-47. doi: 10.1007/s00702-010-0438-z. Epub 2010 Jul 15. Review.

PMID:
20632195
33.

Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6058-63. doi: 10.1073/pnas.0909586107. Epub 2010 Mar 15.

34.

Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits.

Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, Heneka MT.

Neurochem Int. 2010 Nov;57(4):375-82. doi: 10.1016/j.neuint.2010.02.001. Epub 2010 Feb 6.

PMID:
20144675
35.

NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits.

Weberpals M, Hermes M, Hermann S, Kummer MP, Terwel D, Semmler A, Berger M, Schäfers M, Heneka MT.

J Neurosci. 2009 Nov 11;29(45):14177-84. doi: 10.1523/JNEUROSCI.3238-09.2009.

36.

PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.

Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, Heneka MT.

J Neurochem. 2009 Jun;109(6):1779-90. doi: 10.1111/j.1471-4159.2009.06111.x. Epub 2009 May 11.

37.

Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase.

Kummer MP, Maruyama H, Huelsmann C, Baches S, Weggen S, Koo EH.

J Biol Chem. 2009 Jan 23;284(4):2296-306. doi: 10.1074/jbc.M808904200. Epub 2008 Dec 1.

38.

Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism.

Semmler A, Hermann S, Mormann F, Weberpals M, Paxian SA, Okulla T, Schäfers M, Kummer MP, Klockgether T, Heneka MT.

J Neuroinflammation. 2008 Sep 15;5:38. doi: 10.1186/1742-2094-5-38.

39.

PPARs in Alzheimer's Disease.

Kummer MP, Heneka MT.

PPAR Res. 2008;2008:403896. doi: 10.1155/2008/403896.

40.

Artificial vitreous humor for in vitro experiments.

Kummer MP, Abbott JJ, Dinser S, Nelson BJ.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:6407-10.

PMID:
18003488
41.

Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624).

Shaked GM, Kummer MP, Lu DC, Galvan V, Bredesen DE, Koo EH.

FASEB J. 2006 Jun;20(8):1254-6. Epub 2006 Apr 24.

42.

Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.

Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, Berdeaux R, Pietrzik CU, Ladd TB, Golde TE, Koo EH, Weggen S.

J Neurochem. 2006 Jan;96(2):355-65. Epub 2005 Nov 21.

43.
44.

A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation.

Hoffmann J, Twiesselmann C, Kummer MP, Romagnoli P, Herzog V.

Eur J Cell Biol. 2000 Dec;79(12):905-14.

PMID:
11152291
45.

Thyroglobulin type-I-like domains in invariant chain fusion proteins mediate resistance to cathepsin L digestion.

Hitzel C, Kanzler H, König A, Kummer MP, Brix K, Herzog V, Koch N.

FEBS Lett. 2000 Nov 17;485(1):67-70.

46.

Binding and selective detection of the secretory N-terminal domain of the alzheimer amyloid precursor protein on cell surfaces.

Hoffmann J, Pietrzik CU, Kummer MP, Twiesselmann C, Bauer C, Herzog V.

J Histochem Cytochem. 1999 Mar;47(3):373-82.

PMID:
10026239

Supplemental Content

Loading ...
Support Center